References
BERNAL-PACHECO O, LIMOTAI N, GO CL, FERNANDEZ H. Non-motor manifestations in Parkinson’s Disease. Neurologist. 2012; 18(1): 1-16.
PARK A, STACY M. Non-motor symptoms in Parkinson’s disease. J Neurol. 2009; 256(Suppl 3):293-298.
PRICE A, SHIN JC. The impact of Parkinson’s disease on sequence learning: perceptual pattern learning and executive function. Brain Cogn. 2009; 69(2):252-261.
RIGGEAL B, CRUCIAN G, SEIGNOUREL P, JACBSON C, OKUN M, RODRIGUEZ R, FERNANDEZ HH. Cognitive decline tracks motor progression and not disease duration in Parkinson patients. Neuropsychiatry Dis Treat. 2007; 3(6):955-958.
Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sørensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003; 60(3):387-392.
HELY MA, REID WG, ADENA MA, HALLIDAY GM, MORRIS JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008; 23(6):837-844.
POEWE W, WOLTERS E, EMRE M, ONOFRJ M, HSU C, TEKIN S, LANE R, EXPRESS Investigators. Long-term benefits of rivastigmine in dementia associated with Parkinson’s disease: an active treatment extension study. Mov Disord. 2006; 21(4):456-61
RAVINA B, PUTT M, SIDEROWF A, ET AL. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005; 76(7):934-939.
LITVINENKO IV, ODINAK MM, MOGIL’NAYA VI, EMELIN AY. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson’s disease (an open controlled trial). Neurosci Behav Physiol. 2008; 38(9):937-945.
AARSLAND D, BALLARD C, WALKER Z ET AL. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009; 8(7):613-618.
FENELON G, MAHIEUX F, HULON R, ZEIGLER M. Hallucination in Parkinson’s disease: prevalence, phenomenology, and risk facter. Brain. 2000; 123(part4):733-745
HELY MA, MORRIS JG, REID WG, TRAFFICANTE R. Sydney multicenter study of Parkinson’s disease: non-L-dopa-responsive problem dominate at 15 years. Mov Disord. 2005; 20:190-199
FERNANDEZ HH, DONNELLY EM, FRIEDMAN JH. Long-Term Outcome of Clozapine Use for Psychosis in Parkinson’s Patients. Mov Disord. 2004; 19(7):831-833.
READING PJ, LUCE AK, MCKEITH IG. Rivastigmine in the Treatment of Parkinsonian Psychosis and Cognitive Impairment: Preliminary Finding from an Open Trial. Mov Disord. 2001; 16:1171-1174.
FERNANDEZ HH, SEE RH, GARY MF, ET AL. Depressive symptoms in Parkinson disease correlate with impaired global and specific cognitive performance. J Geriatr Psychiatry Neurol. 2009; 22(4):223-227.
BROWN RG, MACCARTHY B, GOTHAM AM, ET AL. Depression and disability in Parkinson’s disease: a follow-up of 132 cases. Psychol Med. 1988; 18(1):49-55.
MARINO S, SESSA E, DI LORENZO G, ET AL. Sertraline in the treatment of depressive disorders in patients with Parkinson’s disease. Neurol Sci. 2008; 29(6):391-395.
BARONE P, POEWE W, ALBRECHT S, ET AL. Pramipexol for the treatment of depressive symptoms in patients with Parkinson´s disease: a randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2010; 9(6):573-580.
BARONE P, SCARZELLA L, MARCONI R, ET AL. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J Neurol. 2006; 253(5):601-607.
OKUN MS, WATTS RL. Depression associated with Parkinson’s disease: clinical features and treatment. Neurology. 2002; 58(4 Suppl 1):S63-S70.
SAWABINI KA, WATTS RL. Treatment of depression in Parkinson’s disease. Parkinsonism Relat Disord. 2004; 10:(Suppl 1):S37-S41.
OKUN MS, FERNANDEZ HH. Will tricyclic antidepressants make a comeback for depressed Parkinson disease patients? Neurology. 2009; 72(10):868-869
SHIBA M, BOWER JH, MARAGANORE DM, ET AL. Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case-control study. Mov Disord. 2000; 15(4):669-677
RICHERD IH, SCHIFFER RB, KURLAN R. Anxiety and Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1996; 8(4):383- 392.
PORAT O, COHEN OS, SCHWARTZ R, HASSIN-BAER S. Association of preoperative symptom profile with psychiatric symptoms following subthalamic nucleus stimulation in patients with Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2009; 21(4):398-405.
KIRSCH-DARROW L, FERNANDEZ HH, MARSISKE M, OKUN MS, BOWERS D. Dissociating apathy and depression in Parkinson disease. Neurology. 2006; 67(1):33-38
PEDERSEN KF, ALVES G, BRØNNICK K, AARSLAND D, TYSNES OB, LARSEN JP. Apathy in drug-naïve patients with incident Parkinson’s disease: the Norwegian ParkWest study. J Neurol. 2010; 257(2):217-223.
ZIEMSSEN T, REICHMANN H. Cardiovascular autonomic dysfunction in Parkinson’s disease. J Neurol Sci.2010; 15; 289(1- 2):74-80.
MATINOLLI M, KORPELAINEN JT, KORPELAINEN R, SOTANIEMI KA, MYLLYLÄ VV. Orthostatic hypotension, balance and falls in Parkinson’s disease. Mov Disord. 2009; 24(5):745-751
PURSIAINEN V, HAAPANIEMI TH, KORPELAINEN JT, SOTANIEMI KA, MYLLYLÄ VV. Sweating in Parkinsonian patients with wearing-off. Mov Disord. 2007; 22(6):828-832.
PROULX M, DE COURVAL FP, WISEMAN MA, PANISSET M. Salivary production in Parkinson’s disease. Mov Disord. 2005; 20(2):204-207
ARBOUW ME, MOVIG KL, KOOPMANN M, ET AL. Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology. 2010; 74(15):1203-1207.
JOHNSTON BT, LI Q, CASTELL JA, CASTELL DO. Swallowing and esophageal function in Parkinson’s disease. Am J Gastroenterol. 1995; 90(10):1741-1746.
TROCHE MS, FERNANDEZ HH. Parkinson disease: sialorrhea and Parkinson disease--novel treatment approaches. Nat Rev Neurol. 2010; 6(8):423-424.
MERELLO M. Sialorrhoea and drooling in patients with Parkinson’s disease: epidemiology and management. Drugs Aging. 2008; 25(12):1007-1019
EDWARDS LL, QUIGLEY EM, PFEIFFER RF. Gastrointestinal dysfunction in Parkinson’s disease: frequency and pathophysiology. Neurology. 1992; 42(4):726-732.
PONSEN MM, STOFFERS D, WOLTERS ECH, BOOIJ J, BERENDSE HW. Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2010; 81(4):396-399.
RAMJIT AL, SEDIG L, LEIBNER J. The relationship between anosmia, constipation, and orthostasis and Parkinson’s disease duration: results of a pilot study. Int J Neurosci. 2010; 120(1):67- 70.
CHOU KL, KOEPPE RA, BOHNEN NI . Rhinorrhea: A common nondopaminergic feature of Parkinson’s disease. Mov Disord. 2011; 26(2):320-323.
MATHERS SE, KEMPSTER PA, LAW PJ, ET AL. Anal sphincter dysfunction in Parkinson’s disease. Arch Neurol. 1989; 46(10):1061-1064.
CERSOSIMO MG, BENARROCH EE. Neural control of the gastrointestinal tract: implications for Parkinson disease. Mov Disord. 2008; 23(8):1065-1075
ZANGAGLIA R, MARTIGNONI E, GLORIOSO M, ET AL. Macrogol for the treatment of constipation in Parkinson’s disease. A randomized placebo-controlled study. Mov Disord. 2007; 22(9):1239-1244.
IACOVELLI E, GILIO F, MECO G, FATTAPPOSTA F, ET AL. Bladder symptoms assessed with overactive bladder questionnaire in Parkinson’s disease. Mov Disord. 2010; 25(9):1203-1209.
GIANNANTONI A, ROSSI A, MEARINI E, DEL ZINGARO M, PORENA M, BERARDELLI A. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson’s disease and multiple system atrophy. J Urol. 2009; 182(4):1453-1457.
DULA E, BUKOFZER S, PERDOK R, GEORGE M; APOMORPHINE SL Study Group. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol. 2001; 39(5):558-563.
O’SULLIVAN JD. Apomorphine as an alternative to sildenafil in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002; 72(5):681
TANBERG F, LARSEN JP, KARLSEN K. A community-base study of sleep disorders in patients with Parkinson’s disease. Mov Disord. 1998; 13:895-899.
KUMAR S, BHATIA M, BEHARI M. Sleep disorders in Parkinson’s disease. Mov Disord. 2002; 17:775-781.
STEVEN S, COMELLA CL, STEPANSKI EJ. Daytime sleepiness and alertness in patients with Parkinson disease. Sleep. 2004; 27:967-972.
AVORN J, SCHNEEWEISS S, SUDARSKY LR, ET AL. Sudden uncontrollable somnolence and medication use in Parkinson’s disease. Arch Neurol. 2005; 62:1242-1248.
ADLER CH, CAVINESS JN, HENTZ JG, LIND M, TIEDE J. Randomized trial of modafinil for treating subjective daytime sleepiness. Mov Disord. 2003; 18:287-293.
VIGNATELLI L, BILLIARD M, CLARENBACH P, ET AL. EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol. 2006; 13:1049-1065.
COMELLA CL, NARDINE TM, DIERICH NJ, STEBBINS GT. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson’s disease. Neurology. 1998; 51(2):526-529.
FRIEDMAN JH, FRIEDMAN H. Fatigue in Parkinson’s disease: a nine-year follow-up. Mov Disord. 2001; 16(6):1120-1122.
MENDONÇA DA, MENEZES K, JOG MS. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord. 2007; 22(14):2070-2076.
BARICHELLA M, CEREDA E, PEZZOLI G. Major nutritional issues in the management of Parkinson’s disease. Mov Disord. 2009; 24(13):1881-1892.
BIENFAIT KL, MENZA M, MARK MH, ET AL. Impulsive smoking in a patient with Parkinson’s disease treated with dopamine agonists. J Clin Neurosci. 2010; 17(4):539-540
LIMOTAI N, OYAMA G, G CL, BERNAL O, ET AL. Addiction like manifestations and Parkinsons Disease: a large single center 9 year experience. Int J Neurosci. 2012; 122(3):145-153
WEINTRAUB D, KOESTER J, POTENZA MN, ET AL. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010; 67(5):589-595.
CERAVOLO R, FROSINI D, ROSSI C, BONUCCELLI U. Impulse control disorders in Parkinson’s disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord. 2009; 15(Suppl 4):S111-S115.
SHAPIRO MA, CHANG YL, MUNSON SK, ET AL. The four As associated with pathological Parkinson disease gamblers: anxiety, anger, age, and agonists. Neuropsychiatr Dis Treat. 2007; 3(1):161-167.
ZAHODNE L., SUSATIA F, BOWERS D, OKUN MS, FERNANDEZ HH. Binge Eating in Parkinson Disease: Prevalence, Correlates, and the Contribution of Deep Brain Stimulation. Abstract # 50 presented at the 21st Annual Meeting of the American Neuropsychiatric Association, 2011.
BERNAL-PACHECO O, OYAMA G, FOOTE KD, DAI YE, WU SS, JACOBSON CE 4TH, LIMOTAI N, ZEILMAN PR, ROMRELL J, HWYNN N, RODRIGUEZ RL, MALATY IA, OKUN MS. Taking a Better History for Behavioral Issues Pre- and Post-Deep Brain Stimulation: Issues Missed by Standardized Scales. Neuromodulation. 2012 Jul 2.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.